1. PHE London / RCGP training online: New HCV Training in Small Bites Emma Burke, PHE London Alcohol and Drug Programme Manager

2. The scale of the problem Estimated 214,000 in the UK have Hepatitis C, 58,000 in London Injecting drug use continues to be the most important risk factor for infection 50% of people who have ever injected are expected to be infected Rates are on the increase in IPED injectors 40% of cases are estimated to be undiagnosed Left untackled HCV will lead to great health costs – both financial and to the individual There is no vaccine, but there is a cure Only 3% of those with the virus are estimated to be treated in any one year Treating people for HCV leads to a range of improved outcomes 2

3. Estimated burden in London 3Hepatitis C epidemiology in London 41,500 HCV RNA positive 40% previously used drugs (no longer inject) 60,000 HCV antibody positive 20% never injected drugs (half of whom are from South Asia) 40% current people who inject drugs Of which Of whom 60% estimated already diagnosed Public Health England. PHE Commissioning Template for Estimating HCV Prevalence by PCT and Numbers Eligible for Treatment. 2014.

4. Figure 1: Trend in anti-HCV prevalence* among people who inject drugs in England: 2003-2013 4Hepatitis C in the UK 2014 report *During 2009 to 2011 there was a phased change in the sample collected in the survey from an oral fluid to dried blood spot (DBS). The sensitivity of the anti-HCV tests on these two sample types is different. The sensitivity of the oral fluid test for anti- HCV is approximately 92%, (28) that on DBS samples is close to 100%. Data presented here have been adjusted for the sensitivity of the oral fluid test.

5. Harm reduction 5Hepatitis C epidemiology in London Level of direct and indirect sharing amongst PWID in London, 2004–2013 Source: Public Health England. Unlinked Anonymous Survey of People Who Inject Drugs.

6. London Hepatitis C Prevalence London Boroughs Total HCV estimates in all populationsLondon Boroughs Total HCV estimates in all populations Barking & Dagenham DAAT 1221 Hounslow DAAT - FIO 1728 Barnet DAAT 1686 Islington DAAT 2231 Bexley DAAT 1178 Kensington & Chelsea DAAT 1137 Brent DAAT 2089 Kingston upon Thames DAAT 865 Bromley DAAT 1356 Lambeth DAAT 3605 Camden DAAT 3002 Lewisham DAAT 2229 City of London DAAT 69 Merton DAAT 1125 Croydon DAAT 2049 Newham DAAT 2785 Ealing DAAT 2183 Redbridge DAAT 1815 Enfield DAAT 1620 Richmond upon Thames DAAT 866 Greenwich DAAT 2111 Southwark DAAT 2921 Hackney DAAT 2100 Sutton DAAT 1110 Hammersmith & Fulham DAAT 1441 Tower Hamlets DAAT 2839 Haringey DAAT 1729 Waltham Forest DAAT 1791 Harrow DAAT 1260 Wandsworth DAAT 2179 Havering DAAT 1133 Westminster DAAT 3100 Hillingdon DAAT 1609

7. London Hepatitis C estimates in current and former injectors London Boroughs HCV estimates in current injectors HCV estimates in previous injectorsLondon Boroughs HCV estimates in current injectors HCV estimates in previous injectors Barking & Dagenham 426502 Hillingdon 397760 Barnet 250976 Hounslow 459739 Bexley 340603 Islington 1331662 Brent 568913 Kensington & Chelsea 483476 Bromley 244800 Kingston upon Thames 200454 Camden 2053676 Lambeth 2272972 City of London 3724 Lewisham 1113821 Croydon 5031000 Merton 220579 Ealing 577981 Newham 1006943 Enfield 413853 Redbridge 250768 Greenwich 1090731 Richmond upon Thames 150513 Hackney 1048766 Southwark 1686911 Hammersmith & Fulham 645579 Sutton 366515 Haringey 673768 Tower Hamlets 1591823 Harrow 160655 Waltham Forest 392755 Havering 273609 Wandsworth 716978 Westminster 2134684

8. What needs to be done? Continued and improved testing rates of drug users (18.9% of eligible clients in the system have no record of a HCV test and 25.4% of those new to treatment) Retest those who have been in the system for some time who have continued risk factors Continued harm reduction advice Embedding testing in any new contracts which are under development Develop pathways from drug treatment into HCV treatment, if pathways are not already in place (good examples are already in place across a range of London boroughs) Decisions to be made about future access to new HCV drugs 8

9. Why should we do it? Increasing testing leads to greater awareness of the disease, enabling people to make better decisions about their health – e.g. continued alcohol consumption Testing offers the opportunity to provide appropriate harm reduction advice to those who test positive which will reduce the further spread of infection Those who test positive have the opportunity to access treatment, potentially leading to a cure Curing those with HCV leads to reduced prevalence in the drug using population and reduces the further spread of infection Currently the prevalence of HCV is increasing 9

10. RCGP training online: new training in short bites Danny Morris, Expert Lead RCGP Hepatitis B and C Part 1

11. Developing competence through education Certificate in Detection, Diagnosis and Management of Hepatitis B and C in Primary Care (Part 1) Online learning and f2f

12. NICE public health guidance Identified a range of social and cultural barriers to hepatitis C testing

13. Lack of awareness among health and social care professionals about the condition and of populations at increased risk and that and this may contribute to a low uptake of testing

15. Repurposing e-learning Commissioned by PHE and designed by the RCGP, the Course is designed to specifically meet learning needs of the range of non-clinical workers Hosted on the RCGP’sOnline Learning Environment (OLE) Free, Online, 2 hour CPD course, using a range of learning materials, opportunity to print a certificate

16. Development Content is jointly badged with PHE and RCGP Content and structure scoped as part of the development process, around identified objectives Materials developed by educational and clinical professionals under the guidance of the RCGP e-learning team, including a range of substance misuse professionals and service users Available to anyone who would like to access the course

17. The audience Non-clinical staff in primary and secondary care including, health visitors, midwives, healthcare assistants and support workers as well as staff in sexual health, genitourinary medicine and HIV clinics People working in drugs services including volunteers and service user advocates and peer educators Staff in community-based criminal justice services Prison and youth offender staff Drug user peer, carer and recovery networks Non- clinical or medical professionals providing health and social care services for people at increased risk of hepatitis C infection and also to people who currently or formerly inject drugs, their peers, including those in recovery

18. Session 2 Session 2: Preventing Hepatitis C Transmission This session will provide participants with core information on HCV transmission routes and risk prevention strategies

19. Session 3 Session 3: Testing and Diagnosis This session will introduce participants to the main tests used to identify exposure to hepatitis C, whether a person is actively infected and to assess and monitor liver health

20. Session 4 Session 4: Treatment and care This session will summarise current hepatitis C (HCV) treatment options, factors that influence treatment effectiveness and potential future treatment opportunities

21. www.elearning.rcgp.org.uk/hepc Hepatitis C: Enhancing Prevention, Testing and Care FREE,AVAILABLE ONLINE NOW RCGP’s Online Learning Environment

22. What can we do? PHE can communicate the availability of the course to local staff / provide you with quarterly data in numbers completing the course in your LA Commissioners can: Encourage promotion of the course and ask local providers to commit to staff completing the course Providers can: Include the course in the induction of new staff / appraisals of existing staff Ensure that all staff are aware of local testing opportunities and pathways to treatment